Orchard Therapeutics Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.00%144.550.7%$910.84m
PFEPfizer Inc. -0.79%37.200.9%$778.56m
BMYBristol-Myers Squibb Co. -0.39%60.411.0%$641.91m
MRKMerck & Co., Inc. 0.32%78.520.7%$631.71m
ABBVAbbVie, Inc. -1.39%83.081.9%$582.83m
LLYEli Lilly & Co. -0.82%142.421.1%$496.70m
AZNAstraZeneca Plc 0.06%52.221.2%$201.24m
NVSNovartis AG -1.40%84.490.2%$143.59m
GSKGlaxoSmithKline Plc -0.71%35.790.2%$135.21m
NVONovo Nordisk A/S -0.21%71.100.1%$70.80m
RGENRepligen Corp. 0.76%173.807.1%$63.90m
RPRXRoyalty Pharma Plc -2.62%39.040.2%$57.66m
SNYSanofi -0.56%49.600.2%$48.49m
PRAXPraxis Precision Medicines, Inc. 0.90%28.000.0%$47.83m
AMAGAMAG Pharmaceuticals, Inc. 0.07%13.6522.1%$44.87m

Company Profile

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.